关键词: font-size:medium, ">帕博利珠单抗；黑色素瘤；预算影响分析

Abstract: Objective： For the purpose of providing evidence for decision makers， the budget impact analysis of the Pembrolizumab introduced into the national medical insurance was carried out， basing on the characteristics of the national basic medical insurance. Methods：From the payer perspective， the budget impact analysis model was established. The time horizon was 2020 to 2024 and the model was aimed at unresectable or metastatic melanoma patients who failed the first-line treatment. The budget impact analysis was carried out with two scenarios (introduced and not introduced into the medical insurance). Results： With Pembrolizumab introduced into the national medical insurance， the incremental expenditure from 2020 to 2024 would be 11.59 million yuan， 13.60 million yuan， 14. 75 million yuan， 15.86 million yuan and 17.06 million yuan， respectively. Accounting for the total expenditure of the national medical insurance， the ratios were 0.000 55%、0.000 53%、0.000 48%、 0.00043% and 0.000 38%， respectively. Conclusion：After Pembrolizumab introduced into the medical insurance catalogue， the number of patients receiving treatment increased， and the expenditure on medical insurance fund increased accordingly. Accounting for the total expenditure of the national medical insurance， the expenditure for treatment of unresectable or metastatic melanoma patients who failed first-line treatment would be decreasing year by year.

Key words: font-size:medium, ">Pembrolizumab； Melanoma； Budget impact analysis